Vascular Endothelial Growth Factor Attenuates Nω-Nitro-L-Arginine Methyl Ester-Induced Preeclampsia-Like Manifestations in Rats

References

• Roberts JM, Gammill HS. Preeclampsia: Recent insights. Hypertension. 2005; 46(6)1243–1249
   PubMed Web of Science ®Google Scholar
• Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005; 308(5728)1592–1594
   PubMed Web of Science ®Google Scholar
• Hunter A, Aitkenhead M, Caldwell C, McCracken G, Wilson D, McClure N. Serum levels of vascular endothelial growth factor in preeclamptic and normotensive pregnancy. Hypertension. 2000; 36(6)965–969
   PubMed Web of Science ®Google Scholar
• Lyall F, Greer IA, Boswell F, Fleming R. Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre-eclampsia. Br J Obstet Gynaecol. 1997; 104(2)223–228
   PubMedGoogle Scholar
• Masuyama H, Suwaki N, Nakatsukasa H, Masumoto A, Tateishi Y, Hiramatrsu Y. Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis. Am J Obstet Gynecol. 2006; 194(2)551–556
   PubMed Web of Science ®Google Scholar
• Mahmound RA, Abdel-Raouf M. Serum endostatin and vascular endothelial growth factor levels in patients with pre-eclampsia. East Mediterr Health J. 2006; 12(1–2)178–187
   PubMedGoogle Scholar
• Savvidou MD, Yu CK, Harland LC, Hingorani AD, Nicolaides KH. Maternal serum concentration of soluble fms-like tyrosine kinase 1 and vascular endothelial growth factor in women with abnormal uterine artery Doppler and in those with fetal growth restriction. Am J Obstet Gynecol. 2006; 195(6)1668–1673
   PubMed Web of Science ®Google Scholar
• Tsao PN, Wei SC, Su YN, Chou HC, Chen CY, Hsieh WS. Excess soluble fms-like tyrosine kinase 1 and low platelet counts in premature neonates of preeclamptic mothers. Pediatrics. 2005; 116(2)468–472
   PubMed Web of Science ®Google Scholar
• Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, Takeda S, Yano T, Tsutsumi O, Taketani Y. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab. 2003; 88(5)2348–2351
   PubMed Web of Science ®Google Scholar
• Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003; 111(5)649–658
   PubMed Web of Science ®Google Scholar
• McKeeman GC, Ardill JE, Caldwell CM, Hunter AJ, McClure N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol. 2004; 191(4)1240–1246
   PubMed Web of Science ®Google Scholar
• Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, Kalluri R. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem. 2003; 278(15)12605–12608
   PubMed Web of Science ®Google Scholar
• Coates BJ, Broderick TL, Batia LM, Standley CA. MgSO4 prevents left ventricular dysfunction in an animal model of preeclampsia. Am J Obstet Gynecol. 2006; 195(5)1398–1403
   PubMed Web of Science ®Google Scholar
• Podjarny E, Losonczy G, Baylis C. Animal models of preeclampsia. Semin Nephrol. 2004; 24(6)596–606
   PubMed Web of Science ®Google Scholar
• Standley CA, Batia L, Yueh G. Magnesium sulfate effectively reduces blood pressure in an animal model of preeclampsia. J Matern Fetal Neonatal Med. 2006; 19(3)171–176
   PubMed Web of Science ®Google Scholar
• Yang Y, Macdonald GJ, Duggan KA. Effects of nitric oxide synthase inhibition on angiotensin receptors and metabolism in the pregnant hypertensive rat. Clin Sci (Lond). 2001; 100(3)319–326
   PubMed Web of Science ®Google Scholar
• Staff AC, Braekke K, Harsem NK, Lyberg T, Holthe MR. Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur J Obstet Gynecol Reprod Biol. 2005; 122(1)33–39
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003; 349(5)427–434
   PubMed Web of Science ®Google Scholar
• Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997; 18(1)4–25
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003; 9(6)669–676
   PubMed Web of Science ®Google Scholar
• Teran E, Escudero C, Vivero S, Molina G, Calle A. NO in early pregnancy and development of preeclampsia. Hypertension. 2006; 47(4)e17
   PubMed Web of Science ®Google Scholar
• van der Weiden RM, Helmerhorst FM. Prostacyclin/thromboxane early changes in pregnancies that are complicated by preeclampsia. Am J Obstet Gynecol. 2004; 190(4)1168–1169
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Hattori T, Kajikuri J, Yamamoto T, Suzumori K, Itoh T. Reduced function of endothelial prostacyclin in human omental resistance arteries in pre-eclampsia. J Physiol. 2002; 545(Pt 1)269–277
   PubMed Web of Science ®Google Scholar
• Klockenbusch W, Goecke TW, Krussel JS, Tutschek BA, Crombach G, Schror K. Prostacyclin deficiency and reduced fetoplacental blood flow in pregnancy-induced hypertension and preeclampsia. Gynecol Obstet Invest. 2000; 50(2)103–107
   PubMed Web of Science ®Google Scholar
• Malatyalioglu E, Adam B, Yanik FF, Kokcu A, Alvur M. Levels of stable metabolites of prostacyclin and thromboxane A2 and their ratio in normotensive and preeclamptic pregnant women during the antepartum and postpartum periods. J Matern Fetal Med. 2000; 9(3)173–177
   PubMedGoogle Scholar
• Bhisitkul RB. Vascular endothelial growth factor biology: Clinical implications for ocular treatments. Br J Ophthalmol. 2006; 90(12)1542–1547
   PubMed Web of Science ®Google Scholar
• Yeoh J, Sims J, Guymer RH. A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006; 7(17)2355–2368
   PubMed Web of Science ®Google Scholar
• Ku DD, Zaleski JK, Liu S, Brock TA. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol. 1993; 265(2 Pt 2)H586–H592
   PubMed Web of Science ®Google Scholar
• van der Zee R, Murohara T, Luo Z, Zollmann F, Passeri J, Lekutat C, Isner JM. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation. 1997; 95(4)1030–1037
   PubMed Web of Science ®Google Scholar
• Khan A, Ashrafpour H, Huang N, Neligan PC, Kontos C, Zhong A, Forrest CR, Pang CY. Acute local subcutaneous VEGF165 injection for augmentation of skin flap viability: Efficacy and mechanism. Am J Physiol Regul Integr Comp Physiol. 2004; 287(5)R1219–R1229
   PubMed Web of Science ®Google Scholar